ÂÜÀòÂÒÂ×

Jim Winkler is Chief Scientific Officer at OnKure, Inc. where he is in charge of matching the company’s unique drugs to the right patient populations. He has spent close to 40 years in the field of drug discovery and development, working at companies of varying sizes including Johnson & Johnson, SmithKline Beecham, GlaxoSmithKline, Array BioPharma, Arvinas, and FORMA Therapeutics. While working for these companies, he gained extensive experience building and leading teams through target validation, early drug discovery, preclinical and clinical development.

Dr. Winkler joined Arvinas as Chief Scientific Officer, helping the new company focus on a novel technology, validating and further advancing this technology, and building a preclinical pipeline, which enabled Arvinas to go public. At Array, Dr. Winkler served as Vice President of Biology and led the discovery and early development division, advancing 16 drugs into the clinic, several of which are in Phase 3 or approved. Dr. Winkler has significant experience in oncology and inflammatory diseases, as well as proficiency in business development and collaboration management. He did his postdoctoral training with Dr. Stanley Crooke at SmithKline Beecham and received a Ph.D. in Pharmacology at the Medical College of Pennsylvania.